Sign In
Buy AGIO
$40.55
-0.680 (-1.65%)
At Close: Jul 13, 2026
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
07:35am, Friday, 10'th Jul 2026
Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat showed mixed Phase 3 results, and competition is coming from Novo Nordisk.
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
11:36am, Wednesday, 08'th Jul 2026
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a decision due on Nov. 1, 2026.
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
11:30am, Wednesday, 08'th Jul 2026
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)
12:32pm, Tuesday, 07'th Jul 2026
The company took a major step toward an accelerated approval of mitapivat in sickle cell disease today. Agios needs to complete a confirmatory trial before a full traditional approval can be granted.
Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone
11:30am, Tuesday, 07'th Jul 2026
Agios stock skyrocketed closer to a profit-taking zone Tuesday after the FDA assigned its sickle cell drug a speedy review.
U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease
07:00am, Tuesday, 07'th Jul 2026
FDA's PDUFA goal date is November 1, 2026 If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWI
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
07:00am, Monday, 29'th Jun 2026
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit
AGIO Stock Surges 35% in Six Months: What's Driving It?
12:25pm, Thursday, 18'th Jun 2026
Agios' shares rose 35% in six months as Aqvesme gains traction, mitapivat expands globally and new ITP rights add to its rare blood disease push.
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
02:07pm, Saturday, 13'th Jun 2026
Agios Pharmaceuticals NASDAQ: AGIO used an investor webcast tied to the 2026 European Hematology Association Congress in Stockholm to highlight new clinical data for mitapivat across thalassemia and s
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript
02:02pm, Saturday, 13'th Jun 2026
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript
Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses showed patients in mitapivat arm had clinic
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
11:25am, Tuesday, 02'nd Jun 2026
Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up to $1B U.S. peak sales potential.
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib
12:28pm, Monday, 01'st Jun 2026
Agios Pharmaceuticals (NASDAQ:AGIO) has secured exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor, under a licensing agreement with South Korea's Oscotec, the company said
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes
10:46am, Monday, 01'st Jun 2026
Agios discontinues development of tebapivat in lower-risk MDS after a phase IIb study misses efficacy goals, shifting focus to a phase II SCD program.
